公开(公告)号：US12018021B2

公开(公告)日：2024-06-25

申请号：US16973701

申请日：2019-06-20

Applicant: UCB Biopharma SRL

Inventor： Pfrafulkumar Tulshibhai Chovatia ,  Rickki Lee Connelly ,  Richard Jeremy Franklin ,  Gregory William Haslett ,  Alistair James Henry ,  James Madden ,  Judi Charlotte Neuss ,  Timothy John Norman ,  Oliver Philps ,  William Ross Pitt ,  Konstantinos Rampalakos ,  Matthew Duncan Selby ,  Selvaratnam Suganthan ,  Giancarlo Trani ,  Zhaoning Zhu

IPC: C07D409/14 ,  C07D333/50 ,  C07D333/78 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  C07D487/04 ,  C07D495/04 ,  C07D495/10 ,  C07D498/10

CPC classification number: C07D409/14 ,  C07D333/50 ,  C07D333/78 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  C07D487/04 ,  C07D495/04 ,  C07D495/10 ,  C07D498/10

Abstract: Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.

公开(公告)号：US11912721B2

公开(公告)日：2024-02-27

申请号：US17102790

申请日：2020-11-24

Applicant: UCB Biopharma SRL ,  Sanofi

Inventor： Teresa De Haro Garcia ,  Michael Deligny ,  Jag Paul Heer ,  Joanna Rachel Quincey ,  Mengyang Xuan ,  Zhaoning Zhu ,  Daniel Christopher Brookings ,  Mark Daniel Calmiano ,  Yves Evrard ,  Martin Clive Hutchings ,  James Andrew Johnson ,  Sophie Jadot ,  Jean Keyaerts ,  Malcolm MacCoss ,  Matthew Duncan Selby ,  Michael Alan Shaw ,  Dominique Louis Leon Swinnen ,  Laurent Schio ,  Yann Foricher ,  Bruno Filoche-Romme

IPC: C07D519/00 ,  C07D491/08 ,  C07D487/08 ,  C07D491/18 ,  C07D495/08 ,  C07D471/18 ,  C07D487/18 ,  C07D493/18 ,  C07D495/18 ,  C07D513/18 ,  C07F7/18 ,  A61K31/4184 ,  A61K31/506 ,  A61K31/55

CPC classification number: C07D519/00 ,  A61K31/4184 ,  A61K31/506 ,  A61K31/55 ,  C07D471/18 ,  C07D487/08 ,  C07D487/18 ,  C07D491/08 ,  C07D491/18 ,  C07D493/18 ,  C07D495/08 ,  C07D495/18 ,  C07D513/18 ,  C07F7/1804

Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

公开(公告)号：US20220073485A1

公开(公告)日：2022-03-10

申请号：US17299137

申请日：2019-11-27

Applicant: UCB Biopharma SRL

Inventor： Anne Marie Foley ,  Jag Paul Heer ,  Fabien Claude Lecomte ,  Nathaniel Julius Thomas Monck ,  Matthew Duncan Selby ,  Mengyang Xuan ,  Lihu Yang

IPC: C07D309/04 ,  C07D413/14

Abstract: A series of functionalised amine derivatives of formula (I) as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.

公开(公告)号：US20210155637A1

公开(公告)日：2021-05-27

申请号：US17102790

申请日：2020-11-24

Applicant: UCB Biopharma SRL ,  Sanofi

Inventor： Teresa De Haro Garcia ,  Michael Deligny ,  Jag Paul Heer ,  Joanna Rachel Quincey ,  Mengyang Xuan ,  Zhaoning Zhu ,  Daniel Christopher Brookings ,  Mark Daniel Calmiano ,  Yves Evrard ,  Martin Clive Hutchings ,  James Andrew Johnson ,  Sophie Jadot ,  Jean Keyaerts ,  Malcolm Mac Coss ,  Matthew Duncan Selby ,  Michael Alan Shaw ,  Dominique Louis Leon Swinnen ,  Laurent Schio ,  Yann Foricher ,  Bruno Filoche-Romme

IPC: C07D519/00 ,  C07F7/18 ,  C07D491/08 ,  A61K31/4184 ,  A61K31/506 ,  A61K31/55 ,  C07D487/08 ,  C07D491/18 ,  C07D495/08 ,  C07D471/18 ,  C07D487/18 ,  C07D493/18 ,  C07D495/18 ,  C07D513/18

Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

公开(公告)号：US20210380573A1

公开(公告)日：2021-12-09

申请号：US17287861

申请日：2019-11-27

Applicant: UCB Biopharma SRL

Inventor： Fabien Claude Lecomte ,  Matthew Duncan Selby

IPC: C07D413/14 ,  A61K45/06

Abstract: A series of substituted benzimidazol-2-one derivatives, and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.

公开(公告)号：US20220332709A1

公开(公告)日：2022-10-20

申请号：US16973701

申请日：2019-06-20

Applicant: UCB Biopharma SRL

Inventor： Pfrafulkumar Tulshibhai Chovatia ,  Rickki Lee Connelly ,  Richard Jeremy Franklin ,  Gregory William Haslett ,  Alistair James Henry ,  James Madden ,  Judi Charlotte Neuss ,  Timothy John Norman ,  Oliver Philps ,  William Ross Pitt ,  Konstantinos Rampalakos ,  Matthew Duncan Selby ,  Suganthan Selvaratnam ,  Giancarlo Trani ,  Zhaoning Zhu

IPC: C07D409/14 ,  C07D495/04 ,  C07D333/78 ,  C07D333/50 ,  C07D409/12 ,  C07D413/12 ,  C07D487/04 ,  C07D417/12 ,  C07D498/10 ,  C07D409/04 ,  C07D413/04 ,  C07D409/06 ,  C07D495/10

Abstract: Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.

公开(公告)号：US20220227764A1

公开(公告)日：2022-07-21

申请号：US17614067

申请日：2020-06-24

Applicant: UCB Biopharma SRL

Inventor： Anne Marie Foley ,  Fabien Claude Lecomte ,  James Thomas Reuberson ,  Matthew Duncan Selby ,  Richard David Taylor ,  Paul Jonathan Hickford ,  Gareth Neil Brace

IPC: C07D471/04

Abstract: A series of substituted fused bicyclic imidazole derivatives, including imidazo[1,2-a]pyridine derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.

公开(公告)号：US11052076B2

公开(公告)日：2021-07-06

申请号：US16619573

申请日：2018-06-12

Applicant: UCB BIOPHARMA SRL

Inventor： Gareth Neil Brace ,  Rose Elizabeth Chappell ,  Hervé Jean Claude Deboves ,  Anne Marie Foley ,  Gregory Foulkes ,  Elizabeth Pearl Jones ,  Fabien Claude Lecomte ,  Joanna Rachel Quincey ,  Monika-Sarah Elisabeth Dorothea Schulze ,  Matthew Duncan Selby ,  Adam Peter Smalley ,  Richard David Taylor ,  Robert James Townsend ,  Zhaoning Zhu

IPC: C07D471/10 ,  C07D487/10 ,  C07D495/10 ,  C07D491/20 ,  A61K31/4439 ,  A61K31/407 ,  A61K31/4155 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/427 ,  A61K31/433 ,  A61K31/437 ,  A61K31/501 ,  A61K31/502 ,  A61K31/506 ,  C07D491/107 ,  C07D519/00

Abstract: A series of substituted spirocyclic 2-oxoindoline derivatives, and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.

公开(公告)号：US10906919B2

公开(公告)日：2021-02-02

申请号：US16220847

申请日：2018-12-14

Applicant: UCB Biopharma SRL ,  Sanofi

Inventor： Teresa De Haro Garcia ,  Michael Deligny ,  Jag Paul Heer ,  Joanna Rachel Quincey ,  Mengyang Xuan ,  Zhaoning Zhu ,  Daniel Christopher Brookings ,  Mark Daniel Calmiano ,  Yves Evrard ,  Martin Clive Hutchings ,  James Andrew Johnson ,  Sophie Jadot ,  Jean Keyaerts ,  Malcolm Mac Coss ,  Matthew Duncan Selby ,  Michael Alan Shaw ,  Dominique Louis Leon Swinnen ,  Laurent Schio ,  Yann Foricher ,  Bruno Filoche-Romme

IPC: C07D519/00 ,  C07F7/18 ,  C07D491/08 ,  A61K31/4184 ,  A61K31/506 ,  A61K31/55 ,  C07D487/08 ,  C07D491/18 ,  C07D495/08 ,  C07D471/18 ,  C07D487/18 ,  C07D493/18 ,  C07D495/18 ,  C07D513/18

Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.